Spyre Therapeutics, Inc. SYRE

Rank #2506 · Nasdaq · $8.4B market cap

Audited by KPMG LLP, no going-concern flag in the latest filing.

Score

11.4

P/E

-24.8

P/B

166.69

ROE

-673.5%

Op. Margin

-27348.0%

Debt Ratio

180%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -24.8x, P/B 166.69x. Ranks in the top 86% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -673.5%. Ranks in the top 99% of the universe.

Safety ★★☆☆☆

Average

Debt ratio 180%. Ranks in the top 59% of the universe.

Growth ★☆☆☆☆

Poor

Revenue decline of 62.0% year over year. Ranks in the top 98% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2016	–	$-0.0B	$-0.0B	$-0.0B	–	-200
2017	–	$-0.0B	$-0.0B	$-0.0B	–	-36
2018	$0.0B	$-0.0B	$-0.0B	$-0.0B	-473.3	-26
2019	$0.0B	$-0.0B	$-0.0B	$0.1B	-531.7	16
2020	$0.0B	$-0.0B	$-0.0B	$0.1B	-1169.3	46
2021	$0.0B	$-0.1B	$-0.1B	$0.1B	–	32
2022	$0.0B	$-0.1B	$-0.1B	$0.1B	–	43
2023	$0.0B	$-0.1B	$-0.1B	$0.1B	-350.3	15
2024	$0.0B	$-0.1B	$-0.1B	$0.1B	-3640.2	87
2025	$0.0B	$-0.2B	$-0.3B	$0.1B	-27348.0	180